826PUse of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE. (23rd October 2018) - Sternberg, C N; Tombal, B; Miller, K; Saad, F; Sartor, O; Sade, J P; Logothetis, C; Bellmunt, J; Dizdarevic, S; Harshman, L C; Logue, J; Baldari, S; et al.